Health Winners & Losers: King Pharma
Health stocks were mixed on relatively light news Monday, with one regulatory-inspired exception.
Big pharma stocks were both up and down -- but not by much -- pushing the Amex pharmaceutical index down about 0.59, or 0.2%, at 317.17. Component King Pharma (kg) continued a second trading day of rebounding from its earnings damage last week. The stock added 36 cents, or 3.4%, to $11.07.
On the biotech side, the Amex and Nasdaq biotechnology indices gained 1.1% and 0.9%.
A component of the Nasdaq index, Cardiome Pharma (CRME), was creamed after the company announced receipt of an "approvable" letter for the intravenous version of its Vernakalant, an experimental drug for irregular heart rhythm.The company said it could take several months to respond to the letter, in which the FDA asked for safety data from ongoing and completed trials. Regulators could require an additional trial, although Cardiome said it is optimistic that won't be the case. The stock was falling $2.55, or 21.3%, to $9.40. Elsewhere, Enzon Pharmaceuticals (ENZN) said it is exploring strategic alternatives for its specialty pharmaceutical business. The company said it might sell the entire business or one or more of its products, and its manufacturing facility in Indiana. Enzon said it has received confidential interest in all or parts of the specialty pharmaceutical business, and is evaluating the sale process. It previously announced it would spin off its biotech business. Shares were up 4 cents to $8.80. In earnings, Obagi Medical (OMPI) edged past Street expectations for its recent quarter but scaled back guidance. The company said it earned 20 cents a share on revenue of $27.8 million, while analysts polled by Thomson Reuters had expected 19 cents a share on $27.2 million.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV